| Code | 4389E | ||||||||||
| MA number | EU/1/23/1751/002 | ||||||||||
| Product Form: | sol inj 1x0,1 ml/4 mg (liek.inj.skl. + ihla + striek.inj.) | ||||||||||
| MA Status: | E - Valid centralised marketing authorisation | ||||||||||
| Type of procedure: | EU | ||||||||||
| MAH, country: | Biosimilar Collaborations Ireland Limited, Ireland | ||||||||||
| Therapeutic Class: | 64 - OPHTHALMOLOGICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Container: | glass vial | ||||||||||
| Route of admin.: | Intravitreal use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(4) similar biological application |
| MA issued: | 15.09.2023 |
| Validity: | 15.09.2028 |
| SmPC + PL: |
European Medicines Agency's database
|
| Safety feature | Yes |
| Data update: | 06.12.2023 |
